NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 123 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $148,512 | -63.9% | 36,400 | +15.9% | 0.01% | -62.5% |
Q3 2022 | $411,000 | +12.0% | 31,400 | +9.8% | 0.02% | 0.0% |
Q2 2022 | $367,000 | +0.8% | 28,600 | +19.7% | 0.02% | 0.0% |
Q1 2022 | $364,000 | -27.6% | 23,900 | -15.8% | 0.02% | -50.0% |
Q4 2021 | $503,000 | +69.4% | 28,400 | +101.1% | 0.03% | +52.4% |
Q3 2021 | $297,000 | – | 14,124 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RHO CAPITAL PARTNERS INC | 3,766,666 | $79,175,000 | 44.14% |
Ponoi II Management, LLC | 1,298,908 | $27,303,000 | 40.46% |
Column Group LLC | 15,396,116 | $323,626,000 | 36.81% |
Ponoi Management, LLC | 1,298,908 | $27,303,000 | 24.24% |
Euclidean Capital LLC | 832,274 | $17,494,000 | 8.50% |
StepStone Group LP | 1,573,357 | $33,072,000 | 2.14% |
Octagon Capital Advisors LP | 200,000 | $4,204,000 | 1.04% |
Redmile Group, LLC | 2,505,118 | $52,658,000 | 0.92% |
BVF INC/IL | 955,000 | $20,074,000 | 0.78% |
Boxer Capital, LLC | 500,000 | $10,510,000 | 0.37% |